Table 3. Association of POMS Scores Arousal and Fatigue after Amphetamine with Individual FAAH Polymorphisms.
| rs6703669 (C/T) | rs3766246 (C/T) | rs324420 (C/A) | rs2295633 (C/T) | |
|---|---|---|---|---|
| (a) Arousala | ||||
| F-value (dF) | 1.65 (4) | 3.37 (4) | 1.58 (2) | 3.04 (4) |
| p-valueb | 0.162 | 0.010* | 0.208 | 0.018* |
| Post hoc (10 mg) | — | |||
| F-value (dF) | — | 3.3 (2) | — | 3.9 (2) |
| p-valuec | — | 0.038* | — | 0.021* |
| (b) Fatigue | ||||
| F-value (DF) | 1.11 (4) | 3.53 (4) | 2.42 (2) | 3.41 (4) |
| p-valueb | 0.350 | 0.009d** | 0.091 | 0.009** |
| Post hoc (10 mg) | ||||
| F-value (dF) | — | 3.7 (2) | 7.4(1) | 4.82 (2) |
| p-valuec | — | 0.028* | 0.007** | 0.009** |
FAAH, fatty acid amide hydrolase; POMS, Profile of Mood States.
a
Arousal adjusted for gender (included as between subject covariate in statistical analyses).
b
Drug-by-genotype interaction effects: p-values assessed by two-way ANOVA/ANCOVA.
c
Post hoc analysis: p-values for main effect of genotype performed using one-way ANOVA/ANCOVA for the 10 mg dose only (placebo and 20 mg doses were not significant).
d
Greenhouse–Geisser Correction.
*p<0.05.
**p<0.01.